| Name |
|---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a...
Benzinga Rankings give you vital metrics on any stock – anytime.
You can purchase shares of Syndax Pharmaceuticals (NASDAQ:SNDX) through any online brokerage.
Other companies in Syndax Pharmaceuticals’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Syndax Pharmaceuticals has a consensus price target of $37.60.
The stock price for Syndax Pharmaceuticals (NASDAQ: SNDX) is $17.84 last updated October 2, 2026 at 2:03 PM EDT.
There are no upcoming dividends for Syndax Pharmaceuticals.
Syndax Pharmaceuticals does not have any upcoming earnings scheduled.
There is no upcoming split for Syndax Pharmaceuticals.
Syndax Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
